Novartis AG (LON: 0K9E) has released topline results from its pivotal global Phase III LUSTER-11 and LUSTER-22 studies.

  • Dec 16, 2019 GMT
  • Team Kalkine

Novartis AG releases topline results from its pivotal global Phase III LUSTER-11 and LUSTER-22 studies

  • The study was aimed at exploring the effectiveness and safety of the investigational oral, once-daily, DP2 receptor contender fevipiprant.
  • The studies included patients who had improperly managed moderate-to-severe asthma, also known as GINA Steps 4 and 5, despite getting inhaled mid-to-high dose corticosteroids and at least one additional controller.

The combined analyses of the LUSTER trials were unable to meet the clinically important level for reducing the rate of moderate-to-severe exacerbation compared to placebo over a 52-week treatment period for either of the two doses of 150mg or 450 mg.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

CLICK HERE FOR YOUR FREE REPORT!
   
x
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK